The Enterprise Value as of December 2024 (TTM) for KalVista Pharmaceuticals, Inc. (KALV) is 394.57M

According to KalVista Pharmaceuticals, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 394.57M. This represents a change of -24.60% compared to the average of 523.27M of the last 4 quarters.

KalVista Pharmaceuticals, Inc. (KALV) Historical Enterprise Value (quarterly & annually)

How has KALV Enterprise Value performed in the past?

The mean historical Enterprise Value of KalVista Pharmaceuticals, Inc. over the last ten years is 202.14M. The current 394.57M Enterprise Value has changed 19.42% with respect to the historical average. Over the past ten years (40 quarters), KALV's Enterprise Value was at its highest in in the July 2024 quarter at 646.63M. The Enterprise Value was at its lowest in in the March 2016 quarter at -26875873.00.

KalVista Pharmaceuticals, Inc. (KALV) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of KalVista Pharmaceuticals, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

KalVista Pharmaceuticals, Inc. (KALV) Average Enterprise Value

How has KALV Enterprise Value performed in the past?

The current Enterprise Value of KalVista Pharmaceuticals, Inc. (KALV) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

KalVista Pharmaceuticals, Inc. (KALV) Enterprise Value vs. Peers

How is KALV’s Enterprise Value compared to its peers?

KalVista Pharmaceuticals, Inc.’s Enterprise Value is less than Crinetics Pharmaceuticals, Inc. (4.71B), greater than Theseus Pharmaceuticals, Inc. (138.26M), less than Kura Oncology, Inc. (659.25M), less than Viridian Therapeutics, Inc. (1.34B), less than Replimune Group, Inc. (908.91M), greater than Nuvectis Pharma, Inc. (72.29M), greater than Lyra Therapeutics, Inc. (22.53M), greater than Kronos Bio, Inc. (7.56M), greater than Gossamer Bio, Inc. (368.34M), less than Syndax Pharmaceuticals, Inc. (985.17M), less than Cogent Biosciences, Inc. (785.70M), less than Cullinan Oncology, Inc. (618.02M), greater than Mersana Therapeutics, Inc. (150.27M), less than Immunocore Holdings plc (1.38B), less than Mirum Pharmaceuticals, Inc. (2.11B), greater than Larimar Therapeutics, Inc. (210.85M), less than Cytokinetics, Incorporated (6.48B), less than DICE Therapeutics, Inc. (1.82B), less than Edgewise Therapeutics, Inc. (2.77B), less than Karuna Therapeutics, Inc. (12.43B), less than Dyne Therapeutics, Inc. (1.93B),

Build a custom stock screener for KalVista Pharmaceuticals, Inc. (KALV) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like KalVista Pharmaceuticals, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

KalVista Pharmaceuticals, Inc. (KALV) and other stocks custom spreadsheet templates

The easiest way to analyze a company like KalVista Pharmaceuticals, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.